Clinical trial
Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood…
NCT00182533 · Hamilton Health Sciences Corporation, Other · Terminated
Key facts
| NCT number | NCT00182533 |
|---|---|
| Title | Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders |
| Official title | Sertraline in the Treatment of Generalized Social Phobia With Comorbidity |
| Lead sponsor | Hamilton Health Sciences Corporation, Other |
| Collaborators | Pfizer Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Phobia, Social, Panic Disorder, Agoraphobia, Obsessive-Compulsive Disorder, Anxiety Disorders, Major Depressive Disorder |
| Intervention type | Drug |
| Interventions | Sertraline, Placebo |
| Enrollment | 170 |
| Start date | Jul 1, 2002 |
| Primary completion | Jan 1, 2018 |
| Completion | Jan 1, 2018 |
| First posted | Sep 16, 2005 |
| Last update posted | Mar 22, 2018 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: